-
1
A study on the expression of Her2/neu in malignant epithelial ovarian tumors
Published 2024-12-01“…A review of the literature highlights a wide range of Her2/neu overexpression or amplifications in ovarian tumors, with reported rates between 8% and 66%. …”
Get full text
Article -
2
-
3
Intradermal DNA Electroporation Induces Cellular and Humoral Immune Response and Confers Protection against HER2/neu Tumor
Published 2015-01-01“…Moreover, we tested the efficacy of intradermal vaccination against Her2/neu antigen in cellular and humoral response induction and consequent protection from a Her2/neu tumor challenge in Her2/neu nontolerant and tolerant mice. …”
Get full text
Article -
4
HER-2/neu Amplification Testing in Breast Cancer by Multiplex Ligation-Dependent Probe Amplification in Comparison with Immunohistochemistry and In Situ Hybridization
Published 2009-01-01“…Background: Assessment of HER-2/neu status in invasive breast cancer is crucial to establish eligibility for trastuzumab and taxane based chemotherapy. …”
Get full text
Article -
5
Stromal Expression of CD10 in Invasive Breast Carcinoma and Its Correlation with ER, PR, HER2-neu, and Ki67
Published 2011-01-01“…Stromal CD10 showed positive correlation with tumour grade, HER2-neu (P=.000), and ki67 (P=.027), negative correlation with ER and PR. …”
Get full text
Article -
6
-
7
HER-2/neu 基因表达对Ⅲ期非小细胞肺癌化疗敏感性的影响
Published 2002-01-01“…【目的】探讨 HER-2/neu 基因表达对Ⅲ期 NSCLC 化疗敏感性的影响。【方法】对22 例中晚期 NSCLC 患者术前化疗后行手术治 疗,标本采用免疫组化法进行 HER-2/neu 检测,分析HER-2/neu 与化疗显效率、疾病进展时间( TTP)的关系。…”
Get full text
Article -
8
LEAPS Vaccine Incorporating HER-2/neu Epitope Elicits Protection That Prevents and Limits Tumor Growth and Spread of Breast Cancer in a Mouse Model
Published 2017-01-01“…The prototype J-LEAPS T cell vaccine for HER-2/neu breast cancer (J-HER) consists of the murine HER-2/neu66–74 H-2d CD8 T cell epitope covalently attached through a triglycine linker to the J-immune cell binding ligand (ICBL) (human β2 microglobulin38–50 peptide). …”
Get full text
Article -
9
Intraoperative Imaging of Positron Emission Tomographic Radiotracers Using Cerenkov Luminescence Emissions
Published 2011-05-01“…CLI, PET, and biodistribution studies revealed target-specific uptake of 89 Zr-DFO-trastuzumab in BT-474 ( HER2/neu positive) versus MDA-MB-468 ( HER2/neu negative) xenografts in the same mice. …”
Get full text
Article -
10
Ribociclib-induced vitiligo in a case of metastatic carcinoma of the breast
Published 2025-01-01“…This report presents a case of HR+ and HER2/neu− metastatic breast carcinoma treated with CDK4/6 inhibitor plus endocrine therapy with the development of vitiligo during the treatment.…”
Get full text
Article -
11
Assessment of Tissue Eosinophilic Infiltration in Invasive Mammary Carcinoma
Published 2024-01-01“…The presence of tissue eosinophilic infiltration can predict HER2/NEU negativity in breast cancer.…”
Get full text
Article -
12
Biomarker panel for early detection of uterine cancer
Published 2024-10-01“…Several biomarkers, including P53, K-RAS, CA-125, HER2/neu, HE4, PTEN, MSI are used for early detection, treatment, and prevention of uterine cancer. …”
Get full text
Article -
13
Papillary Carcinoma of Breast: Clinicopathological Characteristics, Management, and Survival
Published 2022-01-01“…Only two patients were ER negative (both IPC). HER-2 Neu was positive in 3 patients only, out of which 2 died of progressive disease (one EPC and one IPC). …”
Get full text
Article -
14
Comparing the Prognostic Value of PTEN and Akt Expression with the Mitotic Activity Index in Adjuvant Chemotherapy-Treated Node-Negative Breast Cancer patients aged <55 years
Published 2007-01-01“…The MAI was the strongest prognosticator (Hazard Ratio = HR = 2.9, p = 0.01). Her2Neu/p110α/Akt/mTOR features have no additional prognostic value to the MAI. …”
Get full text
Article -
15
A Rare Case Report: Primary Vulvar Adenocarcinoma of Mammary Gland Type
Published 2025-02-01“…The tumor cells were positive for SOX10, TRPS1, and E-cadherin, and negative for ER, PR, and HER-2/neu, ruling out metastatic breast carcinoma. …”
Get full text
Article -
16
Contrast-Enhanced Mammography in the Diagnosis of Breast Angiosarcoma
Published 2021-01-01“…She had a history of a stage I (T1bN0M0) right breast invasive mammary carcinoma, grade 2 (score 7/9) with receptors ER/PR-negative, HER2/neu-positive, diagnosed four years prior to her current presentation. …”
Get full text
Article -
17
Metaplastic Carcinoma Breast in Polycythemic Octogenarian – Lessons Learnt: Case Report
Published 2024-09-01“…Clinically was aT4b lesion, sonomammogram showed BIRADS V lesion and core needle breast biopsy features were suggestive of metaplastic carcinoma breast of adenosquamous type, ER, PR-Positive, Her2Neu-Negative. Patient received preoperative hormonal therapy followed by modified radical mastectomy and postoperative adjuvant chemotherapy and hormonal therapy. …”
Get full text
Article -
18
Molecular Subtypes of Breast Carcinoma and Their Association with Clinicopathological Features
Published 2025-01-01“…Immunohistochemical analysis was done for ER, PR, HER 2 Neu, and Ki-67 and the findings were statistically analyzed for association with clinicopathological parameters. …”
Get full text
Article -
19
Metastatic Extramammary Paget’s Disease of Scrotum Responds Completely to Single Agent Trastuzumab in a Hemodialysis Patient: Case Report, Molecular Profiling and Brief Review of t...
Published 2015-01-01“…We report a case of a complete response to single agent trastuzumab in a hemodialysis patient with metastatic Her2/neu overexpressed EMPD of the scrotum. Molecular profiling of his case as well as 12 other EMPD and 8 mammary Paget disease (MPD) cases was completed and revealed multiple biomarker aberrations. …”
Get full text
Article -
20
Lymphoepithelioma-Like Carcinoma of the Breast: A Case Report Unveiling Several Clinical and Histopathological Challenges
Published 2018-01-01“…The tumor is negative for estrogen and progesterone receptors and did not overexpress HER2/neu. Routine tests for clearance before surgery were performed, and patient was managed by a modified radical mastectomy with axillary lymph node dissection showing no residual tumor. …”
Get full text
Article